Symptom Burden and HRQoL Reported Among Patients With Chronic Hypoparathyroidism: Impact of Treatment With rhPTH(1-84) and With Standard Therapy

Chronic hypoparathyroidism (HypoPT) is a rare disease associated with a variety of symptoms and diminished health-related quality of life (HRQoL). This study aimed to characterise and quantify the symptom burden, HRQoL, and overall disease impact in patients receiving recombinant human parathyroid hormone (rhPTH1-84, Natpar®) for inadequately controlled HypoPT and in symptomatic patients receiving standard therapy (ST; calcium and/or vitamin D supplements). 

Authors

Kristina Chen, Nandini Hadker, Irana Abibova, Lachlan Hanbury-Brown, Montserrat Vera-Llonch, Bart Clarke

Journal

ENDO Meeting, March 2018

ECE Meeting, May 2018

AACE Meeting, May 2018

See all Thought Leadership posts